Can IL-23 be a good target for ulcerative colitis?

Mariangela Allocca; Federica Furfaro; Gionata Fiorino; Daniela Gilardi; Silvia D'Alessio; Silvio Danese

doi:10.1016/j.bpg.2018.05.016

Can IL-23 be a good target for ulcerative colitis?

Best Pract Res Clin Gastroenterol. 2018 Feb-Apr:32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23.

Authors

Mariangela Allocca¹, Federica Furfaro², Gionata Fiorino³, Daniela Gilardi², Silvia D'Alessio⁴, Silvio Danese³

Affiliations

¹ IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. Electronic address: mariangela.allocca@humanitas.it.
² IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy.
³ IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
⁴ Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.

PMID: 30060945
DOI: 10.1016/j.bpg.2018.05.016

Abstract

A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). IL23-blocking has been shown to reduce the severity of inflammation in experimental colitis. Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD). This review aims to discuss the available data on IL-23 and Th17 cell pathways in UC, in order to define the role of IL-23 as possible target for the treatment of UC.

Keywords: Crohn's disease; IL-23; Inflammatory bowel disease; Monoclonal antibody anti-IL23; Th17 cell pathway cytokines; Ulcerative colitis.

Publication types

Review

MeSH terms

Colitis, Ulcerative / drug therapy
Colitis, Ulcerative / pathology
Colitis, Ulcerative / therapy*
Humans
Interleukin-23 Subunit p19 / genetics*
Interleukin-23 Subunit p19 / metabolism

Substances

IL23A protein, human
Interleukin-23 Subunit p19